ROSENBERG MORRIS 4
4 · SEATTLE GENETICS INC /WA · Filed May 18, 2012
Insider Transaction Report
Form 4
ROSENBERG MORRIS
EVP, Development
Transactions
- Sale
Common Stock
2012-05-16$20.80/sh−200$4,160→ 17,643 total - Sale
Common Stock
2012-05-18$21.80/sh−47,776$1,041,517→ 17,643 total - Exercise/Conversion
Common Stock
2012-05-18$4.45/sh+47,776$212,603→ 65,419 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2012-05-16−200→ 17,024 totalExercise: $4.45Exp: 2016-09-05→ Common Stock (200 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2012-05-18−47,776→ 0 totalExercise: $4.45Exp: 2016-09-05→ Common Stock (47,776 underlying) - Exercise/Conversion
Common Stock
2012-05-16$4.45/sh+200$890→ 17,843 total - Exercise/Conversion
Common Stock
2012-05-18$4.45/sh+17,024$75,757→ 34,667 total - Sale
Common Stock
2012-05-18$20.80/sh−17,024$354,099→ 17,643 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2012-05-18−17,024→ 0 totalExercise: $4.45Exp: 2016-09-05→ Common Stock (17,024 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Rosenberg on March 15, 2012.
- [F2]Amount of securities beneficially owned following reported transactions includes 17,643 Restricted Stock Units subject to vesting.
- [F3]Shares shall vest at a rate of 25% on 9/06/07 and monthly thereafter until all the shares are fully vested on 9/06/10.